Survival and clinicopathological characteristics of breast cancer patient according to different tumour subtypes as determined by hormone receptor and Her2 immunohistochemistry. a single institution survey spanning 1998 to 2010.

@article{Fernndez2012SurvivalAC,
  title={Survival and clinicopathological characteristics of breast cancer patient according to different tumour subtypes as determined by hormone receptor and Her2 immunohistochemistry. a single institution survey spanning 1998 to 2010.},
  author={Antonio Garc{\'i}a Fern{\'a}ndez and Nuria Gim{\'e}nez and Manuel Fraile and Sonia Gonz{\'a}lez and Carol Chabrera and Merçe Torras and Clarisa Gonz{\'a}lez and Antonio Soler Salas and Israel Barco and Luis Cirera and Maria Josep Cambra and Enrique Veloso and Antoni Pessarrodona},
  journal={Breast},
  year={2012},
  volume={21 3},
  pages={
          366-73
        }
}
As far as recent breast cancer molecular subtype classification is concerned, much work has dealt with clinical outcomes for triple negative and Her2 patients. Less is known about the course of patients in the remaining subtypes. Molecular classification based on immunohistochemistry is widely available and correlates well with genetic microarray assessment, but at a lower cost. The aim of our investigation was to correlate immunohistochemical subtypes of breast cancer with clinical… CONTINUE READING
Highly Cited
This paper has 40 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 22 extracted citations

Ki-67 is a prognostic marker for hormone receptor positive tumors

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico • 2016
View 1 Excerpt